Trial Profile

Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tagraxofusp (Primary)
Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
Focus Therapeutic Use
Acronyms AML2020

Most Recent Events

30 Jan 2025 Status changed from recruiting to discontinued, due to poor accrual.
12 Dec 2023 Results ( As of July 2023, n=23 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
20 Nov 2023 According to a Menarini media release, data from this study at the 65th American Society of Hematology (ASH) Annual Meeting 2023 December 11, 2023; 6:00 PM - 8:00 PM, San Diego Convention Center, Halls G-H

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com